Arvinas gets FDA/EMA clearance for ARV-393 and ARV-102; Phase 1 trials planned H1 2024

ARVINAS, INC.

FDA authorized IND for ARV-393, a PROTAC BCL6 degrader.
EMA authorized CTA for ARV-102, a PROTAC LRRK2 degrader.
Both first-in-human Phase 1 trials expected to start in H1 2024.
ARV-393 targets BCL6 protein; ARV-102 targets LRRK2 protein.

item 8.01 item 9.01

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-24-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.